Jennifer K. Litton, MD, MD Anderson Cancer Center, shares Feasibility Study with 2 Months of Talazoparib Tumor Volume Decrease of 88i% n 2 Months at Annual Meeting 2018
Feasibility Study with 2 Months of Talazoparib | Tumor Volume Decrease of 88% in 2 Months
